<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00333294</url>
  </required_header>
  <id_info>
    <org_study_id>1839IL/0530</org_study_id>
    <nct_id>NCT00333294</nct_id>
  </id_info>
  <brief_title>Phase II Iressa + Irradiation Followed by Chemo in NSCLC</brief_title>
  <official_title>A Phase II Open-Label Multicentre Study Of The Efficacy Of ZD1839 (IRESSAâ„¢) In Combination With Irradiation Followed By Chemotherapy In Patients With Inoperable Stage III Non Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The objective of this study is to determine wether the ZD1839 associated with a radiotherapy,
      before the beginning of chemotherapy is effective in the treatment of your disease and to
      evaluate the tolerance of these treatments.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">January 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To estimate the objective response rate in patients treated with this drug</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the safety and toxicity of this drug in these patients</measure>
  </secondary_outcome>
  <enrollment>50</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefitinib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radiation therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent.

          -  18 to 75 years inclusive.

          -  At least one measurable lesions histologically confirmed inoperable stage III NSCLC.

          -  WHO performance status of 0 to 2 inclusive.

          -  Adequate pulmonary function, pulmonary dose volume histogram less than or equal to 40
             %.

          -  Life expectancy of at least 6 months.

          -  Using secure contraceptives precautions.

        Exclusion Criteria:

          -  Any previous anti cancer therapy for NSCLC.

          -  Known severe hypersensitivity to these products

          -  Any evidence of clinically active interstitial lung disease

          -  Other co-existing malignancies, symptomatic metastases.

          -  Abnormal blood test

          -  Weight loss of over 15% in the 3 months before the start of the study.

          -  Treatment with a non-approved or investigational drug within 30 days before Day 1 of
             study treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AstraZeneca France Medical Director, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Clermont Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research SIte</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2006</study_first_submitted>
  <study_first_submitted_qc>June 2, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2006</study_first_posted>
  <last_update_submitted>December 16, 2007</last_update_submitted>
  <last_update_submitted_qc>December 16, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

